On August 13, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events" during a live webinar. The recorded webinar and presentation slides are available below.Webinar Faculty:
The webinar discussed:
Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org.
This webinar is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.**Please note that the on-demand webinar is not available for continuing education credits.#ImmuneCheckpointInhibitors #AdverseEvents #PresentationSlides #RecordedWebinar #ClinicalPracticeGuideline #Clinician #NursePractitioner #Oncologist #PatientAdvocate #Pharmacist #PhysicianAssistant #RegisteredNurse #2021
Meeting: SITC Clinical Practice Guideline Webinar – Immune Checkpoint Inhibitor-related Adverse Events; Faculty: Paolo A. Ascierto, MD – Instituto Nazionale Tumori IRCCS, Fondazione 'G. Pascale'; Julie R. Brahmer, MD, MSc – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Marc S. Ernstoff, MD – National Institutes of Health; Gregory A. Masters, MD, FACP, FASCO – Helen F. Graham Cancer Center; Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center; Date: August 13, 202101:02:18